---
title: "Utah Medical Products | 8-K: FY2025 Q3 Revenue: USD 9.812 M"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262487219.md"
datetime: "2025-10-23T19:09:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262487219.md)
  - [en](https://longbridge.com/en/news/262487219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262487219.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/262487219.md) | [English](https://longbridge.com/en/news/262487219.md)


# Utah Medical Products | 8-K: FY2025 Q3 Revenue: USD 9.812 M

Revenue: As of FY2025 Q3, the actual value is USD 9.812 M.

EPS: As of FY2025 Q3, the actual value is USD 0.82.

EBIT: As of FY2025 Q3, the actual value is USD 2.611 M.

### Segment Revenue

-   Total worldwide consolidated sales for Utah Medical Products, Inc. in 3Q 2025 were $9,812, a decrease of 1.9% compared to $10,005 in 3Q 2024.
-   For the first nine months of 2025, total consolidated sales were $29,475, a decrease of 7.2% compared to $31,745 in 9M 2024.

### Operational Metrics

-   Gross Profit for 3Q 2025 was $5,604, a decrease of 3.4% compared to $5,802 in 3Q 2024.
-   Operating Income for 3Q 2025 was $2,611, a decrease of 21.9% compared to $3,343 in 3Q 2024.
-   Net Income for 3Q 2025 was $2,631, a decrease of 26.2% compared to $3,564 in 3Q 2024.
-   Gross Profit Margin for 3Q 2025 was 57.1%, compared to 58.0% in 3Q 2024.
-   Operating Income Margin for 3Q 2025 was 26.6%, compared to 33.4% in 3Q 2024.

### Cash Flow

-   Cash and investments increased to $84,267 at the end of September 30, 2025, from $82,976 at the end of 2024.

### Unique Metrics

-   Adjusted consolidated EBITDA for 3Q 2025 was $4,170, a decrease of 15.9% compared to $4,958 in 3Q 2024.
-   Adjusted consolidated EBITDA for 9M 2025 was $13,493, a decrease of 12.7% compared to $15,447 in 9M 2024.

### Outlook / Guidance

-   Management expects total annual 2025 consolidated sales to be about 7% lower compared to 2024, instead of the initial projection of a 5% decrease.
-   Adjusted consolidated EBITDA for the 2025 calendar year is expected to be in the range of $17 to $18 million.
-   Investors are cautioned that actual events may differ from projections due to various risk factors including global economic conditions and regulatory interventions.

### 相關股票

- [Utah Medical Products (UTMD.US)](https://longbridge.com/zh-HK/quote/UTMD.US.md)

## 相關資訊與研究

- [Assessing International Flavors & Fragrances (IFF) Valuation After Mixed Returns And Portfolio Reshaping](https://longbridge.com/zh-HK/news/281681998.md)
- [How Investors Are Reacting To Peloton (PTON) Expanding Into Commercial Gyms And Refreshing Its Leadership](https://longbridge.com/zh-HK/news/281687103.md)
- [A Look At ADT’s Valuation After Ariel Focus Fund Addition And New Partnership Momentum](https://longbridge.com/zh-HK/news/281687093.md)
- [Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE](https://longbridge.com/zh-HK/news/281704842.md)
- [Geremia Financial Services LLC Purchases New Shares in Apple Inc. $AAPL](https://longbridge.com/zh-HK/news/281704148.md)